Massive deficit in Danish pharma-company due to write-down and divestiture
Increased costs, write-down of the value of subsidiaries and divestiture of a Swedish company has resulted in the doubling of a three-digit million-kroner deficit in a Danish pharmaceutical company.
An increase in turnover is the only bright spot of the yearly financial report from Novozymes Biopharma. Increased costs, loss from divestiture and a significant write-down have extremely adverse effects on the yearly result, which ends in a massive deficit for 2011.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
